Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostate Adenocarcinoma 1Papillomavirus Infections 1Osteosarcoma 1Neuroblastoma 1Melanoma 1Head and Neck Neoplasms 1

Interventions

aldesleukin 9Interleukin-2 9Nivolumab 7fludarabine phosphate 6Dacarbazine 6Cyclophosphamide 6fludarabine 5Temozolomide 4Ipilimumab 4Fluorouracil 4montanide ISA 51 3Surveys and Questionnaires 3Semaxinib 3Radiotherapy 3Radiation 3Mohs Surgery 3Educational Status 3Cisplatin 3Allovectin-7 3zanolimumab 2talabostat 2sonidegib 2poly ICLC 2binimetinib 2Whole-Body Irradiation 2Vinblastine 2Vemurafenib 2Tacrolimus 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Skin Neoplasms × Adjuvants, Pharmaceutic × Clear all
NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

BioNTech SE

Phase 1 Completed
34 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡